Review
doi: 10.1002/jcp.21585.
Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
Affiliations
- PMID: 18781585
- DOI: 10.1002/jcp.21585
Item in Clipboard
Review
Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
J Cell Physiol.
2009 Jan.
Abstract
Acneiform skin eruptions associated with sterile inflammation frequently accompany pharmacological inhibition of signaling through the epidermal growth factor receptor (EGFR) in cancer patients. Here we discuss possible pathogenic mechanisms for this phenomenon linked to control of inflammatory mediators by EGFR blockade in keratinocytes of the outer root sheath of the hair follicle. This discussion is focused on the putative role of EGFR activation in restraining interleukin (IL)-1-dependent inflammatory networks at the hair follicle.
(c) 2008 Wiley-Liss, Inc.
Similar articles
-
The cutaneous epidermal growth factor network: Can it be translated clinically to stimulate hair growth?Dermatol Online J. 2009 Mar 15;15(3):1. Dermatol Online J. 2009. PMID: 19379645 Review.
-
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.Cancer Res. 2009 Jul 15;69(14):5643-7. doi: 10.1158/0008-5472.CAN-09-0487. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584274
-
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.Eur J Cancer. 2007 Mar;43(5):845-51. doi: 10.1016/j.ejca.2006.11.016. Epub 2007 Feb 7. Eur J Cancer. 2007. PMID: 17289377 Review.
-
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.Oncology. 2007;72(3-4):152-9. doi: 10.1159/000112795. Epub 2007 Dec 21. Oncology. 2007. PMID: 18160805
-
The pro-inflammatory and hyperplasiogenic action of interleukin-1 alpha in mouse skin.Prog Clin Biol Res. 1995;391:161-77. Prog Clin Biol Res. 1995. PMID: 8532714 Review. No abstract available.
Cited by
-
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.Oncotarget. 2016 Nov 15;7(46):76087-76100. doi: 10.18632/oncotarget.12590. Oncotarget. 2016. PMID: 27738319 Free PMC article.
-
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).Oncol Rep. 2021 Mar;45(3):891-898. doi: 10.3892/or.2020.7911. Epub 2020 Dec 24. Oncol Rep. 2021. PMID: 33650659 Free PMC article. Review.
-
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.Cancer Biol Ther. 2009 Nov;8(22):2147-52. doi: 10.4161/cbt.8.22.9765. Epub 2009 Nov 7. Cancer Biol Ther. 2009. PMID: 19783899 Free PMC article.
-
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3. Clin Transl Oncol. 2019. PMID: 30284232 Review.
-
Recent advances on the roles of epidermal growth factor receptor in psoriasis.Am J Transl Res. 2019 Feb 15;11(2):520-528. eCollection 2019. Am J Transl Res. 2019. PMID: 30899359 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
